Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ABC Trial: Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer
NCT02927249Phase 3Terminated
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2017
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Arm I (aspirin) with Arm II (Placebo) (2 arms). Primary endpoint: Invasive Disease-Free Survival at 5 years. Started Jan 2017; status: terminated.
02
Drugs
aspirin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02927249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927249.